BFG
TERN

Bleakley Financial Group’s Terns Pharmaceuticals TERN Stock Holding History

Bleakley Financial Group’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-48,296
Closed -$268K – 944
2024
Q4 		$268K Buy
48,296
+34,984
+263% +$237K 0.01% 841
2024
Q3 		$111K Buy
13,312
+2,751
+26% +$22.6K ﹤0.01% 964
2024
Q2 		$71.9K Buy
+10,561
New +$64K ﹤0.01% 966
2024
Q1 		– Sell
-10,452
Closed -$67.8K – 1028
2023
Q4 		$67.8K Buy
+10,452
New +$55.3K ﹤0.01% 913

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Bleakley Financial Group's TERN Position: Q1 2025 in Review

Bleakley Financial Group sold out of Terns Pharmaceuticals (TERN) in Q1 2025, closing a stake of 48,296 shares — an estimated $268K sold.

Bleakley Financial Group first reported a position in TERN in Q4 2023 and held it in 4 quarters. The position peaked at $268K in Q4 2024. 137 funds tracked by Wall St. Rank hold TERN as of Q1 2025.

  • Bleakley Financial Group reported no remaining Terns Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Bleakley Financial Group sold 48,296 Terns Pharmaceuticals shares in Q1 2025, an estimated $268K.
  • Bleakley Financial Group first reported a position in Terns Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Bleakley Financial Group's Terns Pharmaceuticals position peaked at $268K in Q4 2024.
  • 137 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2025.

Based on Bleakley Financial Group's 13F filing for Q1 2025, filed 1 May 2025.